CD22 CAR Optimization for Improved in-Human Activity Following Inadequate CD22 CAR Activity in Phase 1 Clinical Trial PLAT-04
Corinne Summers(Seattle Children's Hospital), Rebecca Gardner(Seattle Children's Hospital), Rimas J. Orentas(Capital Caring), Ashley Wilson(Center for Infectious Disease Research), Jason K. Yokoyama(Seattle Children's Hospital), Wenjun Huang(Lishui Central Hospital), Stephanie Rhea, Blake Baxter, Michael C. Jensen(Seattle Children's Hospital), Colleen Annesley(Unknown), Julie R. Park(Seattle Children's Hospital)
Cited by 9
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|Blood|2017|1.1k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754